João Agostinho
João Agostinho is an expert in Cardiology at Hospital de Santa Maria (Portugal). João Agostinho has authored 52 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 270 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Biochemistry - Internal Medicine - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2014 - 2026
Number : 52
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study. PMID 42902796 — quality of life, amyloidosis, immunoglobulin light-chain amyloidosis, diagnosis, transthyretin amyloidosis | Amyloid | 2026 | 0 |
| Efficacy of tafamidis across age groups in ATTR-CM: insights from real-world data. PMID 42899446 — hospitalization, cardiovascular diseases, cardiology, aged, diuretics, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Cardiol J | 2026 | 0 |
| Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study. PMID 42844536 — phenotype, prealbumin, amyloidosis, therapeutics, frailty, transthyretin amyloidosis | Cardiol Ther | 2026 | 0 |
| Left-Dominant Arrhythmogenic Cardiomyopathy in a Young Athlete: Silent Danger on the Pitch. PMID 42460955 — exercise, research design, genetics, biopsy, myocarditis, ventricular fibrillation, athletes, cardiomyopathies | JACC Case Rep | 2026 | 0 |
| Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM. PMID 42216490 — mortality, heart failure, heart, prealbumin, amyloid, outpatients, cardiomyopathies, transthyretin amyloid cardiomyopathy | Eur J Heart Fail | 2026 | 2 |
Clinical Studies 4
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An Open Label Extension and Safety Monitoring Study of Acoramidis(AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute CM Trial (AG10301) 2024-515092-36-00 — safety, prealbumin, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map